Is NMN or NR better for raising NAD+ levels?

Both effectively raise NAD+ levels. NMN may be slightly more direct (closer to NAD+ in the synthesis pathway), while NR has more published human clinical trial data. The practical difference may be small. Choose reputable, third-party tested products.

Are NAD+ IV drips worth the cost?

NAD+ IV infusions directly raise blood NAD+ levels but are expensive (£200-500+), time-consuming (2-4 hours), and the effects are temporary. Oral precursors (NMN/NR) may provide similar long-term NAD+ elevation at much lower cost, though head-to-head comparisons are lacking.

Can NAD+ reverse ageing?

Animal studies show NAD+ restoration can reverse some markers of ageing (mitochondrial function, DNA repair capacity). However, human evidence for anti-ageing effects is still limited. NAD+ decline is one of several hallmarks of ageing, and addressing it alone is unlikely to 'reverse' ageing.

Is NAD+ safe to take long-term?

Oral NMN/NR supplements appear safe in studies up to 12 months. Long-term data (5+ years) is lacking. The theoretical concern about supporting tumour metabolism has not been confirmed clinically but warrants monitoring. Consult a healthcare professional before long-term supplementation.

Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 8 March 2026

Share:X Post LinkedIn

Longevity & Anti-Ageing•Updated 2026-03-08•6 min read

What Is NAD+? Benefits, Research & Safety

An essential coenzyme involved in cellular energy production and DNA repair, central to ageing research and available as IV infusions and oral precursor supplements.

Share:X Post LinkedIn

Also known as:

Nicotinamide Adenine Dinucleotide

NAD

Coenzyme I

DPN

CLimited human evidenceUK: Sold as 'research only' (UK)WADA: Low sport risk

UK summary: Not a peptide — a coenzyme. NMN and NR oral precursors are sold as supplements. NAD+ IV drip clinics are popular in the UK; clinical evidence for the marketed wellness outcomes is modest, and pricing is high (£200-500+ per drip).

Quick Facts

Overview

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell, essential for fundamental biological processes including energy metabolism, DNA repair, gene expression regulation, and cellular signaling. While technically a dinucleotide rather than a peptide, NAD+ is extensively discussed alongside peptide therapies in longevity and anti-ageing contexts. NAD+ levels decline significantly with age—studies suggest a 50% reduction between ages 40 and 60. This decline is associated with mitochondrial dysfunction, accumulation of DNA damage, chronic inflammation ("inflammaging"), and many age-related diseases. The NAD+ longevity field was revolutionised by the work of David Sinclair and Leonard Guarente, who showed that NAD+-dependent enzymes called sirtuins (particularly SIRT1-7) regulate ageing pathways. Sirtuins require NAD+ as a cofactor, linking NAD+ depletion directly to accelerated ageing. NAD+ can be replenished through several approaches: - **IV NAD+ infusions:** Direct intravenous administration (expensive, time-consuming) - **Precursor supplementation:** NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are orally available precursors - **Lifestyle:** Exercise, caloric restriction, and circadian rhythm optimisation support NAD+ levels NAD+ IV therapy has become popular in longevity clinics worldwide. Oral precursors (particularly NMN) are widely available as supplements. While preclinical evidence is compelling, large-scale human clinical trials are still limited.

Evidence standards summary

NAD+ — evidence and risk at a glance

Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

01Evidence snapshot

CLimited human evidenceOverall grade against our evidence grading methodology.

Not a peptide — a coenzyme. NMN and NR oral precursors are sold as supplements. NAD+ IV drip clinics are popular in the UK; clinical evidence for the marketed wellness outcomes is modest, and pricing is high (£200-500+ per drip).

02Human evidence grade

CLimited human evidenceStrength of evidence from published human trials.

03Preclinical evidence grade

AStrong human evidenceAnimal-model and in-vitro evidence quality.

04Regulatory status

UK: NAD+ precursors (NMN, NR) are available as food supplements. IV NAD+ available at private clinics (not NHS-funded).
EU: NR is available as a supplement. NMN regulatory status varies by country—classified as Novel Food in some jurisdictions.
Notes: NAD+ and its precursors are not classified as medicines. IV NAD+ therapy is available privately but not evidence-based by NHS standards. NMN was briefly under FDA scrutiny in the US but remains available as a supplement. The field is rapidly evolving with ongoing clinical trials.

05Approved medical uses

None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)

06Unapproved / promotional claims

Reverses biological ageing.
Treats long COVID.
Cures chronic fatigue.

07Common internet claims

Marketed by IV-drip clinics at £200-500+ per infusion.
NMN / NR supplements widely sold as longevity precursors.

08Claim vs evidence

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Reverses biological ageing”	E	No	High	Animal studies show NAD restoration affects ageing-related markers; human ageing-reversal claims are not supported.
“IV drips are more effective than oral NMN”	D	Limited	Moderate	IV NAD+ raises blood NAD acutely; whether this drives the wellness outcomes claimed is not established. Oral NMN/NR is far cheaper for sustained elevation.
“Safe long-term”	C	Limited	Moderate	Short-term safety data are encouraging; long-term (5+ years) human safety is not established.

09Safety uncertainty score

Moderate

Safety profile partly characterised; some signals from observational or preclinical data.

10Known adverse signals

IV NAD+: flushing, nausea, chest pressure during infusion.
Theoretical cancer-pathway concerns with sustained NAD+ elevation (mixed signal).
Sterility issues with grey-market IV preparations.

11Drug-interaction uncertainty

Moderate

Some interaction data published; check with a prescriber for your specific medicines.

12Anti-doping status

WADA: Low sport riskWADA strict-liability framing applies.

13UK legal position

UK: Sold as 'research only' (UK)

NAD+ precursors (NMN, NR) are available as food supplements. IV NAD+ available at private clinics (not NHS-funded).

14EU legal position

NR is available as a supplement. NMN regulatory status varies by country—classified as Novel Food in some jurisdictions.

15What this page cannot tell you

Whether IV NAD+ produces any longevity / wellness benefit beyond the placebo and infusion-experience effect.
Long-term safety of sustained pharmacological NAD+ elevation.

16Last reviewed

Last reviewed: 8 March 2026

Next review due: 8 March 2027

Spotted an error or something out of date? Send a correction.

17Citation quality score

BModerate human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

18Research gaps

Phase 3 longevity / disease-prevention outcome trials absent.
Oral vs IV comparative-effectiveness for any defined outcome.

19Safer alternatives / established care pathways

Exercise, sleep, Mediterranean diet — the evidence-based longevity interventions.
NHS investigation for genuine chronic fatigue / long-COVID concerns.

20Doctor discussion prompts

Questions to ask a qualified clinician

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

Is there a clinical reason to elevate NAD+ for my specific situation, or is this a wellness experiment?

Discovery & History

NAD+ was discovered in 1906 by Arthur Harden and William Young as a factor enhancing the rate of fermentation in yeast extracts. Hans von Euler-Chelpin determined its structure and shared the 1929 Nobel Prize with Harden for this work. The role of NAD+ in cellular metabolism was established through mid-20th century biochemistry, with its function in redox reactions (NAD+/NADH) becoming a cornerstone of metabolic understanding. The modern NAD+ renaissance began in the 2000s with two key discoveries: - Leonard Guarente's work showing that sirtuins (NAD+-dependent deacetylases) regulate ageing in yeast, worms, and flies - David Sinclair's research demonstrating that boosting NAD+ levels with precursors like NMN could reverse aspects of ageing in mice The 2013 landmark paper by Gomes et al. showed that declining NAD+ levels drove age-related mitochondrial dysfunction and that NMN supplementation could reverse this. This sparked enormous research interest and commercial development. Clinical trials of NAD+ precursors in humans began around 2017, with NR (Niagen) and NMN studies showing safety and ability to raise NAD+ levels. The human evidence base continues to grow rapidly.

Mechanism of Action

NAD+ is involved in hundreds of enzymatic reactions: **Sirtuin Activation** NAD+-dependent deacetylases crucial for longevity: - SIRT1: Metabolic regulation, DNA repair, inflammation control - SIRT3: Mitochondrial function and antioxidant defence - SIRT6: Genomic stability and telomere maintenance - All sirtuins require NAD+ as an essential cofactor - NAD+ decline reduces sirtuin activity, accelerating ageing **Cellular Energy Production** Central role in metabolism: - NAD+/NADH redox pair essential for glycolysis - Critical for mitochondrial electron transport chain - Required for fatty acid oxidation - Supports cellular ATP production **DNA Repair** Via PARP enzymes: - PARP1 and PARP2 use NAD+ for DNA strand break repair - Chronic DNA damage increases PARP activity - Excessive PARP activation depletes NAD+ pools - Creates a vicious cycle of damage and depletion with ageing **CD38 and NAD+ Consumption** Age-related NAD+ decline mechanism: - CD38 (a NADase) increases with age and inflammation - CD38 is a major consumer of NAD+ in ageing tissues - Inhibiting CD38 may help preserve NAD+ levels - Represents a therapeutic target for NAD+ restoration

Researched Benefits

Based on preclinical and clinical research findings:

1
Restored mitochondrial function in aged mice (preclinical)
2
Improved insulin sensitivity and metabolic parameters (animal studies)
3
Enhanced DNA repair capacity (preclinical)
4
Cardiovascular protection in animal models
5
Neuroprotection and cognitive improvement (animal studies)
6
Safe elevation of blood NAD+ levels in humans (clinical trials of NMN/NR)
7
Potential exercise performance enhancement (limited human data)

Claim vs Evidence

How popular claims about NAD+ stack up against the current research, graded using our public evidence grading methodology.

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Reverses biological ageing”	E	No	High	Animal studies show NAD restoration affects ageing-related markers; human ageing-reversal claims are not supported.
“IV drips are more effective than oral NMN”	D	Limited	Moderate	IV NAD+ raises blood NAD acutely; whether this drives the wellness outcomes claimed is not established. Oral NMN/NR is far cheaper for sustained elevation.
“Safe long-term”	C	Limited	Moderate	Short-term safety data are encouraging; long-term (5+ years) human safety is not established.

Theoretical Dosing & Protocols

⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.

Theoretical Dosage	IV NAD+: 250-750mg per infusion. Oral NMN: 250-1000mg daily. Oral NR: 300-1000mg daily.
Frequency	IV: weekly to monthly sessions. Oral precursors: daily supplementation.
Duration	Ongoing; NAD+ levels decline without continued supplementation
Notes	NAD+ IV infusions are available at longevity clinics (expensive, £200-500+ per session). Oral precursors (NMN, NR) are available as food supplements without prescription. Quality varies significantly between products. Long-term human efficacy data for anti-ageing is still limited.

Administration Routes

Routes studied in research settings (educational only):

Intravenous infusion (IV NAD+)
Oral (NMN and NR precursor supplements)
Sublingual (some NMN formulations)
Intranasal (experimental)

Half-Life	Stability
NAD+ itself has a half-life of hours in circulation; tissue NAD+ pools are maintained by continuous synthesis	IV NAD+ solutions prepared fresh; NMN/NR supplements stable as dry powder

Safety Profile & Known Risks

Commonly Reported Side Effects

IV NAD+: nausea, cramping, chest tightness during infusion
Flushing and warmth (IV)
Headache
Mild GI discomfort with oral precursors
IV infusions can be uncomfortable (2-4 hour duration)

Rare Risks & Concerns

Theoretical concern about supporting tumour metabolism
Interaction with NAD+-dependent drug metabolism
Limited long-term safety data for high-dose supplementation
IV complications (standard IV risks)

Contraindications

Active cancer (theoretical concern about fuelling tumour metabolism)
Pregnancy and breastfeeding (insufficient safety data)
Concurrent use of NAD+-affecting medications

UK & EU Regulatory Context

🇬🇧 United Kingdom

NAD+ precursors (NMN, NR) are available as food supplements. IV NAD+ available at private clinics (not NHS-funded).

🇪🇺 European Union

NR is available as a supplement. NMN regulatory status varies by country—classified as Novel Food in some jurisdictions.

NAD+ and its precursors are not classified as medicines. IV NAD+ therapy is available privately but not evidence-based by NHS standards. NMN was briefly under FDA scrutiny in the US but remains available as a supplement. The field is rapidly evolving with ongoing clinical trials.

Clinical Studies Summary

Are manual therapies, passive physical modalities, or acupuncture effective for the management of patients with whiplash-associated disorders or neck pain and associated disorders? An update of the Bone and Joint Decade Task Force on Neck Pain and Its Associated Disorders by the OPTIMa collaboration.

Our review adds new evidence to the Neck Pain Task Force and suggests that mobilization, manipulation, and clinical massage are effective interventions for the management of neck pain.

Spine J. 2016View on PubMed

NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence.

Overall, NAD⁺ augmentation shows clear biological activity, but clinical effectiveness for anti-aging or wellness outcomes remains inconclusive. Larger, well-designed randomized trials with longer follow-up and prespecified clinically meaningful endpoints are needed, particularly for parenteral approaches.

Ageing Res Rev. 2026View on PubMed

Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review.

NADH supplementation is safe and has a low incidence of side effects. Future investigations are needed to evidence the clinical benefits regarding specific diseases and doses administered.

Am J Physiol Endocrinol Metab. 2024View on PubMed

A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment.

Orr has a patent biosignature and therapeutic approach for neuronal senescence pending outside the scope of this work. No other co-authors have COIs to declare.

Geroscience. 2024View on PubMed

Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial.

Are employees of Elysium Health and own shares in the company. The other authors declare no competing interests.

Nat Aging. 2024View on PubMed

The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.

This trial was registered with ClinicalTrials. gov, NCT04823260, and Clinical Trial Registry - India, CTRI/2021/03/032421.

Geroscience. 2023View on PubMed

Registered Trials & Regulatory Status

Registered trials

Currently recruiting

Furthest phase

Phase 4

Approved product

Yes

Converthera NAD plus Patch

10 of 13 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.

NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome

PHASE1

Status: Not Yet Recruiting · 24 participants · Brigham and Women's Hospital

Conditions: Down Syndrome (DS)

No results postedNCT07278492

To Observe the Clinical Effect of Femoral Nerve Block With Low Concentration of Ropivacaine Based on DPN Grading

N/A

Status: Not Yet Recruiting · 60 participants · Zheng Guo

Conditions: Diabetes Mellitus, Type 2

No results postedNCT06732362

Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients

PHASE2

Status: Recruiting · 138 participants · Christopher Kai Shun Leung

Conditions: Glaucoma

No results postedNCT06991712

Tracing the Metabolic Flux of Orally Administered NAD+ Precursors

PHASE1

Status: Recruiting · 32 participants · Metro International Biotech, LLC

Conditions: Healthy Adults

No results postedNCT06882096

The NAD-HD Study: A Study to Investigate Efficacy and Safety of Nicotinamide Riboside Compared With Placebo in Huntington's Disease

PHASE2

Status: Recruiting · 120 participants · Oslo University Hospital

Conditions: Huntington Disease

No results postedNCT06853743

Evaluation of the Impact of an Alteration of NAD+ Metabolism on the Renal Prognosis of Patients Admitted to Intensive Care (NI-AKI)

Status: Recruiting · 150 participants · Ramsay Générale de Santé

Conditions: Acute Renal Insufficiency, NAD

No results postedNCT07203131

Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)

PHASE3

Status: Active Not Recruiting · 455 participants · Vertex Pharmaceuticals Incorporated

Conditions: Diabetic Peripheral Neuropathic Pain

No results postedNCT06696443

Nicotinamide Adenine Dinucleotide (NAD+) Metabolism in Human Brown Adipose Tissue

Status: Recruiting · 68 participants · University of Turku

Conditions: Obesity, Abdominal

No results postedNCT06627868

Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+

Status: Recruiting · 70 participants · Nutraceuticals Research Institute

Conditions: Healthy Aging

No results postedNCT06919328

Different Amounts of Moxibustion in the Treatment of DPN: A Clinical RCT Study

Status: Active Not Recruiting · 90 participants · Zhejiang Chinese Medical University

Conditions: Diabetic Peripheral Neuropathy, Pain, Moxibustion

No results postedNCT06330233

Effectiveness of Qualia NAD+ Supplementation on Intracellular NAD Levels

Status: Recruiting · 200 participants · Qualia Life Sciences

Conditions: NAD+ Levels in the Blood

No results postedNCT06505967

Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus

PHASE1/PHASE2

Status: Recruiting · 78 participants · National Heart, Lung, and Blood Institute (NHLBI)

Conditions: Systemic Lupus Erythematosus (Sle)

No results postedNCT06032923

Adverse event reports (FDA FAERS)

fatigue8
headache6
insomnia5
nausea5
anxiety4
asthenia3
cough3
covid-193
dizziness3
palpitations3

FDA FAERS spontaneous reports. A report is not proof the substance caused the event, and an absence of reports is not evidence of safety.

Source: ClinicalTrials.gov and openFDA. Updated automatically.

Looking for NAD+?

Source research-grade NAD+ from a trusted UK supplier — third-party tested with certificate of analysis.

View at Supplier

Frequently Asked Questions

Questions to ask a qualified clinician about NAD+